Abstract: The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to a patient in need thereof on-demand.

Abstract: Disclosed is a lidded magazine (100) for holding plural generally flat sample collection cards (10) in spaced parallel relation, the magazine is open at its top and includes upstanding opposed side walls (110,120), each wall (110,120) further including plural opposed pairs of inwardly extending wall ribs (112,122) spaced along each wall (110,120) to provide therebetween card accepting slots, a first slot dimension (W) being defined by the spacing between an interior face (154) of each wall, the magazine being characterised in that the walls (110,120) at the top (152) of each slot (150) are tapered outwardly such that the first dimension (W) is greatest at the top of the slot (150).

Abstract: A method for producing an olefin product, including the steps of converting a hydrocarbon feedstock to an unsaturated hydrocarbon stream through a steam cracking process in an olefins production plant; combusting hydrogen to provide at least some of the heating duty to the steam cracking process, wherein the hydrogen has a carbon intensity less than about 1.0 kg CO2e/kg H2, wherein the hydrogen is produced using a hydrogen production process; providing at least some of the required energy for the hydrogen production process from a biomass power plant; and processing the unsaturated hydrocarbon stream to recover the olefin product. The olefin product may comprise ethylene having a well-to-gate carbon intensity less than about 0.6 kg CO2e/kg C2H4, or may comprise propylene having a well-to-gate carbon intensity less than about 0.6 kg CO2e/kg C3H6.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Abstract: The present invention provides an integrated process for preparing 2,3,3, 3-tetrafluoropropene (1234yf), the process comprising: (a) vapour phase catalytic fluorination of a first composition comprising 3,3,3-trifluoro-2-chloro-prop-1-ene (CF3C—CNCH2, 1233xf) with hydrogen fluoride (HF) in a fluorination reactor to produce a fluorination product stream comprising 1,1,2,2-pentafluoropropane (245cb), HF and HCI; (b) vapour phase catalytic dehydrofluorination composition comprising 245cb in a dehydrofluorination reactor to produce a dehydrofluorination product stream comprising 1234yf and HF; wherein the fluorination product stream and the dehydrofluorination product stream are combined and subjected to (c) purification to produce a composition comprising 245cb and a 1234yf product stream.

Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: A method of operating a rechargeable sodium ion cell, wherein the cell comprises an anode material which is a disordered carbon and a nickel-containing sodium oxide cathode material comprises: in a formation charge phase, charging the cell to a first voltage at which sodium is irreversibly liberated from the cathode material; and in a subsequent charge-discharge cycle, charging the cell to a second voltage lower than the first voltage. The voltage to which the cell is charged in the formation charge phase may be selected such that the amount of sodium irreversibly liberated from the cathode material in the formation charge phase substantially equals the amount of sodium deposited in a surface electrolyte layer on the anode in the formation charge phase.

Abstract: The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR? and the treatment of diseases related to the modulation of ROR?. The present invention also en-compasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Abstract: A coated metal ion containing material, includes a core comprising a metal ion containing material and a hydrophobic coating at least partially coating the core. A method of forming a coated metal ion containing material includes: combining the metal ion containing material and one or more hydrophobic coating materials; and milling the metal ion containing material and the one or more hydrophobic coating materials to coat the metal ion containing material with the one or more hydrophobic coating materials to provide a core comprising the metal ion containing material and a hydrophobic coating at least partially coating the core.

Abstract: A metal-ion electrochemical cell contains a composite anode (40) comprising a support matrix (40a) and electrochemically active metal droplets (40b) dispersed through the support matrix (40a). The metal droplets have a melting point of 100° C. or lower, and may have a melting point of 40° C. or lower or a melting point of 20° C. or lower. The cell also includes a composite cathode (60) containing an intercalation material for the metal, and a conducting electrolyte medium (50) located between the anode and the cathode. The metal-ion consists of one or more of: sodium, zinc, magnesium, aluminium and calcium. In another embodiment, the cell further contains a conductive spacer layer disposed between the anode current collector and the composite anode. In this embodiment the metal-ion may consist of one or more of: lithium, sodium, zinc, magnesium, aluminium and calcium.

Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.